NCT07234851Enrolling by invitation
Understanding Mechanisms of Synaptic Degeneration Underlying Clinical Symptoms in Patients With MDs and NDs.
SYNAPSING's POSTMORTEM AND IN VITRO STUDIES OF SYNAPSE DYSFUNCTION
Source: ClinicalTrials.gov · Last updated 11 Dec 2025
Brief summary (registry, in English)
Clinical Study A. Retrospective Neuropathological Study of Synapse dysfunction. This is a cross-sectional study of patients retrospectively collected from existing postmortem collections and from existing collections of iPSC-derived neurons. Postmortem tissue and iPSC-derived neurons from age and sex-matched unaffected volunteers without a MD or ND diagnosis are used as controls.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 17 Mar 2025
- Start date
- 1 Feb 2025
- Primary completion date
- 30 Jun 2029
- Lead sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- NCT number
- NCT07234851
What you commit to
- Study type: Observational
- Planned participants: 150
- From 1 Feb 2025 to the primary completion date, 30 Jun 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- For schizophrenia, cases displaying additional neurological or psychiatric conditions, such as histories of substance use disorder will be excluded. Postmortem delay \>24h (to minimise perimortem confounding variables potentially affecting tissue quality.
Other
- Postmortem delay \>24h (to minimise perimortem confounding variables potentially affecting tissue quality.
Who the study is looking for
- Age group: Midlife brain donors (age-at-death\>40).
- Sex distribution: % Female in schizophrenia (23%), major depressive disorder and controls (40%), bipolar disorder and controls (55%). These percentages match those typically found in these disorders.
- Antemortem diagnosis of schizophrenia (paranoid-subtype diagnoses only to minimise the impact of potential confounding factors on the results and ensure homogeneity across schizophrenia subjects), major depression or bipolar disorder. Diagnoses are confirrmed antemortem by a psychiatrist using Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria, as recorded in the deceased individuals' medical records.
- Age group: Latelife brain donors (age-at-death\>50).
- Sex distribution: Alzheimer's disease (60%), frontotemporal dementia (65%). These percentages match those typically found in these diseases.
- Neuropathological confirmation of Alzheimer's disease or frontotemporal lobar degeneration (C9orf72 repeat expansion carrier)Alzheimer's disease
Age in the registry: 40 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Research Institute Sant Pau Coordinator of this site? Confirm its status | Barcelona | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.